Cytokine gene expression and production by human LPS-stimulated mononuclear cells are inhibited by sulfated heparin-like semi-synthetic derivatives

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 9, 2004, Pages 1657-1662

  Gori, Anna Maria ^b   Attanasio, M ^b   Gazzini, A ^b   Rossi, L ^b   Lucarini, L ^b   Miletti, S ^a   Chini, J ^a   Manoni, M ^a   Abbate, R ^b   Gensini, G F ^b  

^a INALCO RSM SpA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Heparin derivatives; Interleukin 10; Proinflammatory cytokines; TNF alpha mRNA expression

Indexed keywords

CYTOKINE; HEPARIN DERIVATIVE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; POLYSACCHARIDE; POLYSACCHARIDE SULFATE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; SUPERNATANT;

CYTOKINES; GENE EXPRESSION; HEPARIN; HUMANS; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; POLYSACCHARIDES, BACTERIAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 19944432597     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00866.x     Document Type: Article

References (30)

1. Guyton Jr, Rosenberg RD, Clowes AW, Karnovsky MJ. Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res 1980; 46: 625-34.
2. Folkman J. Regulation of angiogenesis: a new function of heparin. Biochem Pharmacol 1985; 34: 905-9.
3. Au YPT, Montgomery KF, Clowes AW. Heparin inhibits collagenase gene expression mediated by phorbol ester-responsive element in primate arterial smooth muscle cells. Circ Res 1992; 70: 1062-9.
4. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993; 82: 3253-58.
5. Weiler JM, Edens RE, Linhardt RJ, Kapelanski DP. Heparin and modified heparin inhibit complement activation in vivo. J Immunol 1992; 148: 3210-15.
6. Xie X, Rivier AS, Zakrzewicz A, Bernmoulin M, Zeng XL, Wessel HP, Schapira M, Spertini O. Inhibition of selectin-mediated cell adhesion and prevention of acute inflammation by nonanticoagulant sulfated saccharides. J Biol Chem 2000; 275: 34818-25.
7. Yang KA, Hilli HR. Functional biology of the granulocyte monocyte series. In: Bick RL, ed. Hematolgy: Clinical and Laboratory Practice. St Louis: Mosby, 1993; 1077-92.
8. Cavaillon JM, Haeffner-Cavaillon N. Structure-function relationships to core oligosaccharide. In: Morrison DC, Ryan JL, eds. Bacterial Endotoxic Lipopolysaccharide. Boca Raton, FL: CRC, 1992.
9. Ingalls RR, Heine H, Lien E, Yoshimura A, Golenbock DT. Lipopolysaccharide recognition, CD14, and lipopolysaccharide receptors. Bacterial Sepsis Septic Shock 1999; 13: 341-53.
10. Gallay P, Jongeneel CV, Barras C, Burnier M, Baumgartner JD, Glauser MP, Heumann D. Short time exposure to lipopolysaccharide is sufficient to activate human monocytes. J Immunol 1993; 150: 5086-93.
11. Attanasio M, Gori AM, Giusti B, Pepe C, Comeglio P, Brunelli T, Prisco D, Abbate R, Gensini GF, Neri Serneri GG. Cytokine gene expression in human LPS- and IFNγ-stimulated mononuclear cells is inhibited by heparin. Thromb Haemost 1998; 79: 959-62.
12. Myrvang-Hogasen AK, Abrahamsen TG. Heparin suppresses lipopolysaccharide-induced monocyte production of several cytokines, but simultaneously stimulates C3 production. Thromb Res 1995; 80: 179-84.
13. Wang JG, Mu JS, Zhu HS, Geng JG. N-desulfated non-anticoagulant heparin inhibits leukocyte adhesion and transmigration in vitro and attenuates acute peritonitis and ischemia and reperfasion injury in vivo. Inflamm Res 2002; 51: 435-43.
14. Kouretas PC, Kim YD, Cahill PA, Myers AK, To LN, Wang Y-N, Sitzmann JV, Hannan RL. Nonanticoagulant heparin prevents coronary endothelial dysfunction after brief ischemia-reperfusion injury in the dog. Circulation 1999; 99: 1062-8.
15. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993; 82: 3253-8.
16. Thourani VH, Brar SS, Kennedy TP, Thornto LR, Watts JA, Ronson RS, Zhao ZQ, Sturrock AL, Hoidal JR, Vinten-Johansen J. Nonanticoagulant heparin inhibits NF-kappaB activation and attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2000; 48: H2084-H2093.
17. Anastase-Ravion S, Carreno MP, Blondin C, Ravion O, Champion J, Chaubet F, Haeffner-Cavaillon N, Letourneur D. Heparin-like polymers modulate proinflammatory cytokine production by lipopolysaccharide-stimulated human monocytes. J Biomed Mater Res 2002; 60: 375-83.
18. Boyum A. Isolation of lymphocytes, granulocytes and macrophages. Scand J Immunol 1976; 5: 9-15.
19. Manzoni M, Bergomi S, Cavazzoni V. Extracellular K5 polysaccharide of Escherichia coli: production and characterization. J Bioactive Compat Polym 1993; 8: 251-7.
20. Casu B, Gennaro U. A conductimetric method for the determination of sulphate and carboxyl groups in heparin and other mucopolysaccharides. Carbohyd Res 1975; 39: 168-76.
21. Chomczynski P, Sacchi N. Single step-method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Ann Biochem 1987; 162: 156-9.
22. Waal MR, Abrams J, Bennet B, Figdor CG, Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209-20.
23. Wang L, Brown JR, Varki A, Esko JD. Heparin's anti-inflammatory effects require glucosamine 6 O-sulphation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002; 110: 127-36.
24. Tangelder GJ, Arfors KE. Inhibition of leukocyte rolling in venules by protamine and sulfated polysaccharides. Blood 1991; 7 1565-71.
25. Barzu T, Lormeau JC, Petitou M, Michelson S, Choay J. Heparin-derived oligosaccharides: affinity for acid fibroblast growth factor and effect on its growth-promoting activity for human endothelial cells. J Cell Physiol 1989; 140: 538-48.
26. Baskin P, Doctrow S, Klagsbrun M, Svahn CM, Folkman J, Vlodavsky I. Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparinase and heparin-like molecules. Biochemistry 1989; 28: 1737-43.
27. Matzner Y, Marx G, Drexler R, Eldor A. The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thromb Haemost 1984; 52: 134-7.
28. Castellot JJ Jr, Choay J, Lormeau JC, Petitou M, Sache E, Karnovsky MJ. Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. Evidence for a pentasaccharide sequence that contains a 3-O sulphate group. J Cell Biol 1986; 102: 1979-84.
29. Fryer A, Huang YC, Rao G, Jacoby D, Mancilla E, Whorton R, Piantadossi CA, Kemmedy T, Hoidal J. Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J Pharmacol Exp Ther 1997; 282: 208-19.
30. Koening A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulphate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1997; 101: 877-89.